NOWOX Oxygen Therapy Monitoring Device

NCT ID: NCT00800072

Last Updated: 2014-02-27

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

COMPLETED

Clinical Phase

NA

Total Enrollment

10 participants

Study Classification

INTERVENTIONAL

Study Start Date

2008-11-30

Study Completion Date

2010-02-28

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

The purpose of this study is to evaluate the duration of oxygen use recorded by the NOWOX, under usual conditions of daily living, in patients with chronic obstructive respiratory disease requiring oxygen therapy.

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Long Term Oxygen Therapy (LTOT) is one of the main non pharmacologic treatments for patients with severe lung disease. This continuous or sub-continuous oxygen supplementation is generally introduced at home in patients who have chronic cardio respiratory failure and severe resting hypoxemia to maintain sufficient blood oxygenation and therefore preserve vital organ function.

LTOT effectiveness has mainly been evaluated and documented in patients with COPD, which also accounts for most of its prescriptions. In these patients, LTOT has been shown to have a beneficial impact on haemodynamics, exercise capacity, lung mechanics and mental state. Its implementation was furthermore associated with reduced yearly hospitalisation days and increased survival Measuring adherence is an extremely important and under-evaluated component of oxygen therapy. NOWOX, medical device has been designed,developed and manufactured to measure adherence to LTOT and additionally to measure patient's respiration rate

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Chronic Obstructive Pulmonary Disease

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

NA

Intervention Model

SINGLE_GROUP

Blinding Strategy

NONE

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

oxygen therapy

one experimental device assigned to each of the 10 patients including in the study for an experiemental session duration of 6 hours

Group Type EXPERIMENTAL

NOWOX

Intervention Type DEVICE

one experimental device assigned to each of the 10 patients including in the study for an experiemental session duration of 6 hours

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

NOWOX

one experimental device assigned to each of the 10 patients including in the study for an experiemental session duration of 6 hours

Intervention Type DEVICE

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* Male or female patient aged ≥ 18 years and ≤ 75 years,
* Having a documented diagnosis of moderately severe to severe chronic obstructive respiratory disease
* Hospitalised or out-patient requiring transient or long term oxygen therapy,
* Able to be weaned from oxygen for several consecutive minutes (around 30 minutes, SpO2 at rest on room air should not drop \< 85%),
* Able to read
* Willing and able to complete the requirements of this study including providing his/her signature for the written informed consent.

Exclusion Criteria

* Clinically unstable patient,
* Any contraindication to perform a light cycling exercise, according to the 2003 ATS/ACCP guidelines
* Tracheostomy,
* Nasal obstruction or acute rhinitis occurring in the week prior to selection,
* For female patient:
* Pregnant,
* Positive urinary pregnancy test
* Lactating mother or lack of efficient contraception
* Clinically significant or uncontrolled cardiac, hepatic, renal, gastrointestinal, endocrine, metabolic, autoimmune, neurological or psychiatric disorders which may interfere with the study procedures,
* Known allergic reactions to medical material compounds used in the study
* Drug abuse or psychic disorders
* Legal status which prohibits informed consent,
* Participation in any interventional clinical trial within 30 days prior to selection.
Minimum Eligible Age

18 Years

Maximum Eligible Age

75 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

No

Sponsors

Meet the organizations funding or collaborating on the study and learn about their roles.

Air Liquide SA

INDUSTRY

Sponsor Role lead

Responsible Party

Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.

Responsibility Role SPONSOR

Principal Investigators

Learn about the lead researchers overseeing the trial and their institutional affiliations.

Anh-Tuan DINH-XUAN, Professor-MD

Role: PRINCIPAL_INVESTIGATOR

Department of Physiology - Cochin University Hospital - FRANCE

Locations

Explore where the study is taking place and check the recruitment status at each participating site.

Cochin University Hospital

Paris, , France

Site Status

Countries

Review the countries where the study has at least one active or historical site.

France

Other Identifiers

Review additional registry numbers or institutional identifiers associated with this trial.

ALMED-07-MD-015

Identifier Type: -

Identifier Source: org_study_id

More Related Trials

Additional clinical trials that may be relevant based on similarity analysis.